Pulse Biosciences, Inc. (PLSE) Appoints Laureen DeBuono to Its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Pulse Biosciences Appoints Laureen DeBuono to Its Board of Directors
October 5, 2021 8:00 AM EDTHAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation (NPS) technology, today announced the appointment of Laureen DeBuono to its Board of Directors. Concurrent to Ms. DeBuonos appointment, Kenneth Clark has resigned from the Board of Directors.
We are delighted and honored to welcome Laureen to the Pulse Biosciences Board, said Robert Duggan, Chairman of the Pulse Biosciences Board of Directors. Laureen is an accomplished executive with a track record of driving growth and creating shareholder value through operational,... More
